Meta Information
ID:nicotine-non-tobacco
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Nicotine is a developmental toxicant that readily crosses the placenta and can cause fetal harm, including low birth weight, premature delivery, and potential long-term neurodevelopmental issues.
Actionable advice:
This should be strictly avoided during pregnancy.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
If you are pregnant or breast-feeding, only use this medicine on the advice of your health care provider
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Nicotine passes into breast milk and can cause irritability, poor feeding, and increased heart rate in the nursing infant.
Actionable advice:
It should be avoided completely while breastfeeding.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
If you are pregnant or breast-feeding, only use this medicine on the advice of your health care provider
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
avoid
Target id:
/condition/severe-cardiovascular-disease
Target name:
Severe or Recent Cardiovascular Events
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
In the immediate period following a heart attack, or with uncontrolled arrhythmias or severe angina, nicotine's stimulant effects on the heart can be dangerous.
Actionable advice:
Use should be avoided immediately following a heart attack or with severe, unstable heart disease.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
heart disease, recent heart attack, or irregular heartbeat
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
avoid
Target id:
/intervention/varenicline
Target name:
Varenicline (Chantix)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both nicotine and varenicline act on nicotinic receptors; concurrent use increases the risk of adverse effects like nausea, headache, and sleep disturbances without improving cessation rates.
Actionable advice:
Nicotine replacement therapy should not be used while taking varenicline unless directed by a physician.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Drug interactions with tobacco smoking
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
avoid
Target id:
/dietary/acidic-beverages
Target name:
Acidic Beverages (Coffee, Juice, Soda)
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
0.25
Hours after target:
0.25
Description:
Acidic drinks lower the pH in the mouth, which ionizes nicotine and severely impairs its absorption through the buccal mucosa from gum, lozenges, or pouches.
Actionable advice:
Acidic drinks should be avoided for 15 minutes before and after using oral nicotine products.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Acidic beverages reduce absorption of nicotine from gum
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/2107334/
Action type:
avoid
Target id:
/class/cyp1a2-substrates
Target name:
CYP1A2 Substrates (e.g., Clozapine, Olanzapine, Theophylline)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
This is an interaction with smoking cessation, for which nicotine is used. Tobacco smoke (not nicotine) induces CYP1A2 enzymes. Upon quitting smoking, levels of drugs metabolized by CYP1A2 can rise to toxic levels.
Actionable advice:
If using nicotine to quit smoking, doses of CYP1A2-metabolized drugs must be carefully monitored and likely reduced by your doctor.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Cytochrome P450 1A2 induction by tobacco smoke
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
monitor
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Nicotine causes vasoconstriction and release of catecholamines, which can increase blood pressure and counteract the therapeutic effects of blood pressure-lowering medications.
Actionable advice:
Blood pressure should be monitored regularly, as dose adjustments of antihypertensive medication may be needed.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
high blood pressure not controlled with medication
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
adjust_with_prescriber
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Nicotine can increase blood glucose levels by stimulating the release of catecholamines, potentially reducing the effectiveness of medications used to manage diabetes.
Actionable advice:
Blood glucose levels are best monitored closely, as adjustments to diabetes medication may be necessary.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
stomach ulcer or diabetes
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
monitor
Target id:
/class/stimulants
Target name:
Stimulant Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Nicotine has stimulant properties that can add to the cardiovascular effects (increased heart rate and blood pressure) of other stimulants like amphetamines or methylphenidate.
Actionable advice:
This is best used with caution, and it is a good idea to monitor blood pressure and heart rate closely when combining it with other stimulants.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Nicotine can increase your heart rate
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
monitor
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
4
Hours after target:
null
Description:
As a central nervous system stimulant, nicotine can interfere with sleep onset and reduce sleep quality. Patches worn overnight may cause vivid dreams or nightmares.
Actionable advice:
Fast-acting nicotine products are best avoided within 4 hours of bedtime.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
if you have vivid dreams or other sleep disturbances
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
separate
Target id:
/condition/hepatic-impairment
Target name:
Hepatic Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Since nicotine is primarily metabolized by the liver, severe liver disease can reduce its clearance, leading to higher blood levels and increased risk of side effects.
Actionable advice:
A lower dose is best used, with monitoring for side effects, in severe liver disease.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Nicotine clearance is reduced in hepatic impairment
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
monitor
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Severe kidney disease can reduce the clearance of nicotine and its metabolites, leading to higher blood levels and increased risk of side effects.
Actionable advice:
A lower dose is best used, with monitoring for side effects, in severe kidney disease.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Renal impairment reduces nicotine clearance
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
monitor
Target id:
/condition/peptic-ulcer-disease
Target name:
Peptic Ulcer Disease (PUD)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Nicotine may delay the healing of peptic ulcers by reducing gastric blood flow and inhibiting pancreatic bicarbonate secretion.
Actionable advice:
This is best used with caution in those with an active peptic ulcer.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
stomach ulcer or diabetes
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
informational_none
Target id:
/class/cyp2a6-inhibitors
Target name:
CYP2A6 Inhibitors
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Drugs that inhibit the CYP2A6 enzyme (e.g., methoxsalen, tranylcypromine) can slow down nicotine metabolism, leading to higher plasma concentrations and an increased risk of nicotine toxicity.
Actionable advice:
This is best used with caution, and a lower nicotine dose may be worth considering when co-administered with strong CYP2A6 inhibitors.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Nicotine is primarily metabolized by CYP2A6
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
informational_none
Target id:
/class/cyp2a6-inducers
Target name:
CYP2A6 Inducers
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Drugs that induce the CYP2A6 enzyme (e.g., rifampin) can speed up nicotine metabolism, leading to lower plasma concentrations and potentially reduced efficacy or increased craving.
Actionable advice:
It is worth being aware that higher or more frequent doses of nicotine may be required when taking a CYP2A6 inducer.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
CYP2A6 inducers reduce nicotine plasma levels
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
adjust_with_prescriber
Target id:
/intervention/adenosine
Target name:
Adenosine
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Nicotine may reduce the hemodynamic effects (e.g., vasodilation) of adenosine, potentially making it less effective when used for cardiac stress testing or treating supraventricular tachycardia.
Actionable advice:
It is a good idea to let a doctor know about nicotine use before receiving adenosine.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Nicotine antagonizes adenosine effects
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
informational_none
Target id:
/intervention/caffeine
Target name:
Caffeine
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both nicotine and caffeine are CNS stimulants; using them together can lead to additive effects like jitteriness, increased heart rate, and anxiety.
Actionable advice:
Caffeine intake is worth keeping in mind, as it may amplify nicotine's stimulant side effects.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Smoking induces CYP1A2 increasing caffeine clearance
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
informational_none
Target id:
/class/benzodiazepines
Target name:
Benzodiazepines
Severity:
minor
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The stimulant effects of nicotine may counteract the sedative and anxiolytic effects of benzodiazepines.
Actionable advice:
The effectiveness of benzodiazepines for sedation or anxiety may be reduced.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Smoking increases benzodiazepine clearance
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
informational_none
Target id:
/dietary/meal
Target name:
Any Caloric Meal
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
0.25
Hours after target:
0.25
Description:
Eating or drinking while using oral nicotine products (gum, lozenge, pouch) can interfere with proper placement in the mouth and wash away nicotine before it can be absorbed.
Actionable advice:
Eating or drinking is generally best avoided for 15 minutes before and during use of oral nicotine products.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Try to avoid alcohol, coffee and other beverages you
Label source:
FDA label: Nicotine transdermal (NicoDerm CQ)
Action type:
avoid
Target id:
/class/h2-receptor-antagonists
Target name:
H2 Receptor Antagonists (e.g., Cimetidine)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Cimetidine can inhibit liver enzymes responsible for nicotine metabolism, potentially increasing nicotine levels and the risk of side effects.
Actionable advice:
Nicotine effects may be stronger when taking cimetidine; other H2 blockers have less effect.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
H2-receptor antagonists may alter nicotine absorption
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/10523724/
Action type:
informational_none